
Sign up to save your podcasts
Or


Philipp Spycher, co-founder and CEO of Araris Biotech, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Araris is working to develop a linker technology for antibody-drug conjugates that enables attachment of any payload to ‘off the shelf’ antibodies without the need of prior antibody engineering.
By John Simboli5
77 ratings
Philipp Spycher, co-founder and CEO of Araris Biotech, shares his thoughts with BioBoss host John Simboli about leadership in biopharma and how Araris is working to develop a linker technology for antibody-drug conjugates that enables attachment of any payload to ‘off the shelf’ antibodies without the need of prior antibody engineering.

3,069 Listeners

1,952 Listeners

1,099 Listeners

2,357 Listeners

948 Listeners

791 Listeners

124 Listeners

321 Listeners

6,066 Listeners

94 Listeners

10,017 Listeners

522 Listeners

152 Listeners

248 Listeners

184 Listeners